Praziquantel for schistosomiasis in pregnancy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Praziquantel for the treatment of schistosomiasis during human pregnancy.Bulletin of the World Health Organization · 2018
   Trial
2. Anthelmintic medication with focus on first-trimester exposure: an evaluation of pregnancy outcomes based on the Embryotox cohort.Scientific reports · 2026
   Article
3. Zoonotic Schistosomiasis: The Crossroads Between Animal and Human Schistosomiasis in Africa: Narrative Review.Health science reports · 2025
   Article
4. Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data.Wellcome open research · 2022
   Article

Corrections and comments

• Comment on
  Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as